Key Quantitative Figures

Standalone Financial Results (Q2 FY2026):

  • Revenue from Operations: ₹1414.06 lakh
  • Other Income: ₹88.84 lakh
  • Total Revenue: ₹1502.90 lakh
  • Total Expenses: ₹1420.63 lakh
  • Profit Before Tax: ₹82.27 lakh
  • Tax Expense: ₹21.43 lakh (Current Tax: ₹22.29 lakh, Deferred Tax: -₹0.86 lakh)
  • Net Profit: ₹60.84 lakh
  • EPS: ₹0.61 (Basic and Diluted)
  • Paid-up Equity Share Capital: ₹1000.00 lakh (Face Value ₹10 each)

Standalone Financial Results (H1 FY2026):

  • Total Revenue: ₹3026.92 lakh
  • Profit Before Tax: ₹163.56 lakh
  • Net Profit: ₹121.60 lakh
  • EPS: ₹1.22 (Basic and Diluted)

Consolidated Financial Results (Q2 FY2026):

  • Revenue from Operations: ₹2284.53 lakh
  • Other Income: ₹74.56 lakh
  • Total Revenue: ₹2359.09 lakh
  • Total Expenses: ₹2316.93 lakh
  • Loss Before Tax: -₹367.93 lakh
  • Tax Expense: ₹38.61 lakh (Current Tax: ₹43.49 lakh, Deferred Tax: -₹4.88 lakh)
  • Net Loss: -₹404.23 lakh
  • EPS: -₹1.45 (Basic and Diluted)
  • Net loss attributable to owners: -₹144.733 lakh
  • Net loss attributable to non-controlling interest: -₹259.502 lakh

Consolidated Financial Results (H1 FY2026):

  • Total Revenue: ₹4443.59 lakh
  • Loss Before Tax: -₹325.77 lakh
  • Net Loss: -₹399.81 lakh
  • EPS: -₹0.81 (Basic and Diluted)
  • Net loss attributable to owners: -₹80.623 lakh
  • Net loss attributable to non-controlling interest: -₹319.192 lakh

Dates of Action

  • Board Meeting Date: November 6, 2026
  • Meeting Time: 01:00 PM to 01:30 PM
  • Period Ended: September 30, 2026
  • Auditor Review Date: November 6, 2026

Parties Involved

  • Board of Directors of Medico Intercontinental Limited
  • Statutory Auditors: M/s. V Goswami & Co (FRN: 0128769W)
  • Partner: Vipul Goswami (Membership No: 119809)
  • Managing Director: Samir D Shah (DIN: 03350268)
  • Subsidiaries included in consolidation: Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, Azillian Healthcare Private Limited, Calborn Lifescience Private Limited, Medico Lab (Joint Venture)

Subsidiary Information

Subsidiaries and joint venture included in consolidated results with total assets of ₹7594.19 lakh as at September 30, 2026, and total revenues of ₹1504.66 lakh for Q2 FY2026 and ₹2848.88 lakh for H1 FY2026. Their financial results were not reviewed by the group auditor but were reviewed and certified by the management of the respective companies.

Financial Position (Standalone as at September 30, 2026)

  • Total Assets: ₹6893.83 lakh
  • Total Equity: ₹4206.10 lakh
  • Non-Current Liabilities: ₹1723.04 lakh
  • Current Liabilities: ₹964.68 lakh
  • Inventories: ₹1531.90 lakh
  • Trade Receivables: ₹1689.97 lakh
  • Cash and Cash Equivalents: ₹210.10 lakh

Cash Flow (Standalone H1 FY2026)

  • Net Cash from Operating Activities: -₹231.72 lakh
  • Net Cash from Investing Activities: ₹325.22 lakh
  • Net Cash from Financing Activities: -₹88.49 lakh
  • Net Increase in Cash: ₹5.02 lakh
  • Cash at Beginning: ₹216.00 lakh
  • Cash at End: ₹221.01 lakh

Additional Information

  • The company operates in a single segment (pharmaceuticals)
  • The company has continued with old Income Tax rates and is evaluating options under section 115BAA of the Income Tax Act, 1961
  • Previous period figures have been re-grouped/reclassified for comparability
  • The financial results are available on the company website: www.medicointercontinental.com